Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of ...
The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...
Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...
There are some challenges of CAR T cell therapy, which are as follows: CAR T cell therapy can have significant side effects, ...
Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...
Immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant—erased all detectable traces of a brain cancer.
An immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant in a Stanford ...
The most common adverse events were cytopenias, cytokine release syndrome and rash ... giving the company rights to uza-cel, ...
AZoLifeSciences on MSN1d
A Closer Look at CAR T-Cell Therapy — Successes, Challenges, And FutureT-cell therapy is a revolutionary immunotherapy approach in which T cells are genetically modified to express a receptor that ...
Microfluidic chips that mimic the complex human cervical environment provide a platform to study the reproductive tract and ...
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing CohortInterim Data from Atopic Dermatitis Trial ...
At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback